Thrombolytic Therapy in Acute Care: A Comprehensive Overview of Therapeutic Approaches and Clinical Outcomes

Abstract

Thrombolytic therapy is a vital component in the treatment of acute illnesses such as myocardial infarction, ischemic stroke, and pulmonary embolism. Its purpose is to minimize tissue damage and restore perfusion. With an emphasis on the use of tissue plasminogen activator (tPA) and other drugs, the timing of administration, and the related clinical results, this study thoroughly analyses the therapeutic approaches to thrombolysis. Research shows that by lowering death and morbidity, early administration—ideally, during the first few hours after symptom onset—significantly improves outcomes. Treatment options have increased, especially for patients who are not good candidates for systemic thrombolysis, because to developments in thrombolytic drugs and delivery systems, such as catheter-directed thrombolysis and ultrasound-enhanced thrombolysis. It is important to carefully choose and monitor patients receiving thrombolytic treatment since, despite its advantages, it has some contraindications, including the possibility of haemorrhagic consequences. A customized treatment plan is essential to optimize effectiveness while avoiding side effects, as demonstrated by the outcomes of several clinical trials. In Result it should be noted that research is still being done to determine the best ways to employ thrombolytic treatment to enhance patient outcomes in acute care settings.